The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,418
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,009
Alallam, B., Altahhan, S., Taher, M., Nasir, M. H. M., & Doolaanea, A. A. (2020) · Pharmaceuticals · doi:10.3390/ph13080158 · Cited by 56
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 53
Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.022 · Cited by 60
Prokaryotic Argonaute Proteins as a Tool for Biotechnology
Kropocheva, E., Lisitskaya, L., Agapov, A., Musabirov, A. A., Kulbachinskiy, A. V., & Esyunina, D. (2022) · Molecular Biology · doi:10.1134/s0026893322060103 · Cited by 54
A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing
Wang, Y., Qi, T., Liu, J., Yang, Y., Wang, Z., Wang, Y., Wang, T., Li, M., Li, M., Lu, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo6405 · Cited by 56
Progress of targeted genome modification approaches in higher plants
Cardi, T., & Stewart, C. N. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1975-1 · Cited by 57
Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes
Soyars, C. L., Peterson, B. A., Burr, C. A., & Nimchuk, Z. L. (2018) · Plant and Cell Physiology · doi:10.1093/pcp/pcy079 · Cited by 50
Nagata, K., Takahashi, M., Matsuba, Y., Okuyama-Uchimura, F., Sato, K., Hashimoto, S., Saito, T., & Saido, T. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04238-0 · Cited by 52
CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice
Li, J., Wang, L., Hua, X., Tang, H., Chen, R., Yang, T., Das, S., & Xiao, J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.005 · Cited by 54
Sretenovic, S., Yin, D., Levav, A., Selengut, J., Mount, S. M., & Qi, Y. (2020) · Plant Communications · doi:10.1016/j.xplc.2020.100101 · Cited by 53
Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
Himeda, C. L., Jones, T. I., & Jones, P. L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.001 · Cited by 54
History of genome editing: From meganucleases to CRISPR
Tröder, S. E., & Zevnik, B. (2021) · Laboratory Animals · doi:10.1177/0023677221994613 · Cited by 55
Systems Metabolic Engineering of Escherichia coli
Choi, K. R., Shin, J. H., Cho, J. S., Yang, D., & Lee, S. Y. (2016) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0010-2015 · Cited by 53
Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing
García, B., Lee, J., Edraki, A., Hidalgo-Reyes, Y., Erwood, S., Mir, A., Trost, C. N., Seroussi, U., Stanley, S. Y., Cohn, R. D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.017 · Cited by 51
Scalable characterization of the PAM requirements of CRISPR–Cas enzymes using HT-PAMDA
Walton, R. T., Hsu, J. Y., Joung, J. K., & Kleinstiver, B. P. (2021) · Nature Protocols · doi:10.1038/s41596-020-00465-2 · Cited by 49
Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing
Chen, Y., Hu, Y., Wang, X., Luo, S., Yang, N., Chen, Y., Li, Z., Zhou, Q., & Li, W. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100264 · Cited by 49
Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Al‐Megrin, W. A. I., Aljamaan, A. N., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087052 · Cited by 53
Efficient plant genome engineering using a probiotic sourced CRISPR-Cas9 system
Zhong, Z., Liu, G., Tang, Z., Xiang, S., Yang, L., Huang, L., He, Y., Fan, T., Liu, S., Zheng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41802-9 · Cited by 58
Kolesnik, V. V., Nurtdinov, R. F., Oloruntimehin, E. S., Karabelsky, A. V., & Malogolovkin, A. S. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1607 · Cited by 53
Rational engineering of minimally immunogenic nucleases for gene therapy
Raghavan, R. S., Friedrich, M., King, C., Vo, C.-D.-T., Strebinger, D., Lash, B., Kilian, M., Platten, M., Macrae, R. K., Song, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55522-1 · Cited by 56
Self-citationThe PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
Seidah, N. G. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.2 · Cited by 53
A Review of CRISPR-Based Genome Editing: Survival, Evolution and Challenges
Ahmad, H. I., Ahmad, M. J., Asif, A. R., Adnan, M., Iqbal, M. K., Mehmood, K., Muhammad, S. A., Bhuiyan, A. A., Elokil, A., Du, X., et al. (2018) · Current Issues in Molecular Biology · doi:10.21775/cimb.028.047 · Cited by 52
Wang, Q., Liu, S., Liu, Z., Ke, Z., Li, C., Yu, X., Chen, S., & Guo, D. (2018) · Virus Research · doi:10.1016/j.virusres.2018.04.002 · Cited by 49
Delivery systems of CRISPR/Cas9-based cancer gene therapy
Biagioni, A., Laurenzana, A., Margheri, F., Chillà, A., Fibbi, G., & Rosso, M. D. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0127-2 · Cited by 52
Lee, Y., Mout, R., Luther, D. C., Liu, Y., Castellanos-García, L. J., Burnside, A., Ray, M., Tonga, G. Y., Hardie, J. M., Nagaraj, H., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900041 · Cited by 51
CRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 54
Koga, K., Yamagata, R., Kohno, K., Yamane, T., Shiratori‐Hayashi, M., Kohro, Y., Tozaki‐Saitoh, H., & Tsuda, M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.034 · Cited by 52
In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system
Li, Q., Su, J., Liu, Y., Jin, X., Zhong, X., Mo, L., Wang, Q., Deng, H., & Yang, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.005 · Cited by 52
Tang, T. J., Han, Y., Wang, Y., Huang, H., & Qian, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.677587 · Cited by 52
Gumusgoz, E., Guisso, D. R., Kasiri, S., Wu, J., Dear, M., Verhalen, B., Nitschke, S., Mitra, S., Nitschké, F., & Minassian, B. A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01040-7 · Cited by 51
Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modules
Shams, A., Higgins, S. A., Fellmann, C., Laughlin, T. G., Oakes, B. L., Lew, R., Kim, S., Lukarska, M., Arnold, M. L., Staahl, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25992-8 · Cited by 50
Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 58
Potato improvement through genetic engineering
Martínez-Prada, M. D. M., Curtin, S. J., & Gutierrez-Gonzalez, J. J. (2021) · GM crops & food · doi:10.1080/21645698.2021.1993688 · Cited by 50
In vivo epigenome editing and transcriptional modulation using CRISPR technology
Lau, C., & Suh, Y. (2018) · Transgenic Research · doi:10.1007/s11248-018-0096-8 · Cited by 51
Therapeutic Genome Editing in Cardiovascular Diseases
German, D. M., Mitalipov, S. M., Mishra, A., & Kaul, S. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.004 · Cited by 52
AcrIIA5 Inhibits a Broad Range of Cas9 Orthologs by Preventing DNA Target Cleavage
Song, G., Zhang, F., Zhang, X., Gao, X., Zhu, X., Fan, D., & Tian, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.078 · Cited by 49
Self-citationStrategies for the CRISPR-Based Therapeutics
Li, B., Niu, Y., Ji, W., & Dong, Y. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.006 · Cited by 52
Efficient base editing with high precision in rabbits using YFE-BE4max
Liu, Z., Chen, S., Shan, H., Jia, Y., Chen, M., Song, Y., Lai, L., & Li, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2244-3 · Cited by 47
Wu, J., Wang, M., Yang, X. W., Yi, C., Jiang, J. D., Yu, Y., & Ye, H. (2020) · Nature Communications · doi:10.1038/s41467-020-17530-9 · Cited by 50
Guyon, A., Rousseau, J., Bégin, F.-G., Bertin, T., Lamothe, G., & Tremblay, J. P. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.02.032 · Cited by 55
Zhang, Y., Nishiyama, T., Li, H. Z., Huang, J. H., Atmanli, A., Sanchez‐Ortiz, E., Wang, Z., Mireault, A. A., Mammen, P. P. A., Bassel‐Duby, R., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.014 · Cited by 49
The Power of CRISPR-Cas9-Induced Genome Editing to Speed Up Plant Breeding
Cao, H. X., Wang, W., Hiền, L. T. T., & Vu, G. T. H. (2016) · International Journal of Genomics · doi:10.1155/2016/5078796 · Cited by 52
Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 50
Wang, Q., Chen, S., Xiao, Q., Liu, Z., Liu, S., Hou, P., Zhou, L., Hou, W., Ho, W., Li, C., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0375-0 · Cited by 49
Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing
Lu, J. Q., Zhao, C., Zhao, Y., Zhang, J., Zhang, Y., Chen, L., Han, Q., Yue, Y., Peng, S., Ai, R., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1222 · Cited by 46
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
Highly efficient base editing with expanded targeting scope using SpCas9‐NG in rabbits
Liu, Z., Shan, H., Chen, S., Chen, M., Song, Y., Lai, L., & Li, Z. (2019) · The FASEB Journal · doi:10.1096/fj.201901587r · Cited by 46
Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 52
Progress and Perspective of CRISPR‐Cas9 Technology in Translational Medicine
Zheng, R., Zhang, L., Parvin, R., Su, L., Chi, J., Shi, K., Ye, F., & Huang, X. (2023) · Advanced Science · doi:10.1002/advs.202300195 · Cited by 56
Continuous directed evolution of a compact CjCas9 variant with broad PAM compatibility
Schmidheini, L., Mathis, N., Marquart, K. F., Rothgangl, T., Kissling, L., Böck, D., Chanez, C., Wang, J. P., Jínek, M., & Schwank, G. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01427-x · Cited by 49
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee, Y., Santos, R. D., Al‐Rasadi, K., & Rizzo, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.018 · Cited by 49
Structural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9
Hirano, S., Abudayyeh, O. O., Gootenberg, J. S., Horii, T., Ishitani, R., Hatada, I., Zhang, F., Nishimasu, H., & Nureki, O. (2019) · Nature Communications · doi:10.1038/s41467-019-09741-6 · Cited by 47
Self-citationMolecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 49
Genome Editing in Cardiovascular Biology
Seeger, T., Porteus, M. H., & Wu, J. C. (2017) · Circulation Research · doi:10.1161/circresaha.116.310197 · Cited by 48
Concerns regarding ‘off-target’activity of genome editing endonucleases
Kadam, U. S., Shelake, R. M., Chavhan, R. L., & Suprasanna, P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.027 · Cited by 47
Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications
Bećirović, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04175-8 · Cited by 52
Insights into the Mechanism of CRISPR/Cas9-Based Genome Editing from Molecular Dynamics Simulations
Bhattacharya, S., & Satpati, P. (2022) · ACS Omega · doi:10.1021/acsomega.2c05583 · Cited by 51
Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs
Stahl, E. C., Sabo, J. K., Kang, M. H., Allen, R., Applegate, E., Kim, S., Kwon, Y., Seth, A., Lemus, N., Salinas-Rios, V., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.019 · Cited by 51
An adenine base editor variant expands context compatibility
Xiao, Y., Wu, Y., & Tang, W. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01994-3 · Cited by 48
Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease
Hung, S. S. C., McCaughey, T., Swann, O. G., Pébay, A., & Hewitt, A. W. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.05.001 · Cited by 49
Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells
Hindriksen, S., Bramer, A. J., Truong, M. A., Vromans, M. J. M., Post, J. B., Verlaan-Klink, I., Snippert, H. J. G., Lens, S. M. A., & Hadders, M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179514 · Cited by 46
CRISPR in Animals and Animal Models
Shrock, E., & Güell, M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 45
Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery
Ahmad, G., & Amiji, M. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.014 · Cited by 48
VEGF and VEGFB Play Balancing Roles in Adipose Differentiation, Gene Expression, and Function
Jin, H., Li, D., Wang, X., Jia, J., Chen, Y., Yao, Y., Zhao, C., Lü, X., Zhang, S., Togo, J., et al. (2018) · Endocrinology · doi:10.1210/en.2017-03246 · Cited by 47
CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
Lone, B. A., Karna, S. K. L., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2018) · Genetics Research International · doi:10.1155/2018/3797214 · Cited by 48
Raitskin, O., Schudoma, C., West, A., & Patron, N. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211598 · Cited by 50
Structure of the OMEGA nickase IsrB in complex with ωRNA and target DNA
Hirano, S., Kappel, K., Altae-Tran, H., Faure, G., Wilkinson, M. E., Kannan, S., Demircioglu, F. E., Yan, R., Shiozaki, M., Yu, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-05324-6 · Cited by 45
Self-citationNew advances in CRISPR/Cas-mediated precise gene-editing techniques
Richardson, C., Kelsh, R. N., & Richardson, R. J. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049874 · Cited by 48
Development of delivery strategies for CRISPR‐Cas9 genome editing
Liu, Q., Yang, J., Xing, Y., Zhao, Y., & Liu, Y. (2023) · BMEMat · doi:10.1002/bmm2.12025 · Cited by 47
Zhu, K., Celwyn, I. J., Guan, D., Yang, X., Wang, X., Hu, W., Jiang, C., Cheng, L., Casellas, R. C., & Lazar, M. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.09.010 · Cited by 47
Ibba, G., Piu, C., Uleri, E., Serra, C., & Dolei, A. (2018) · Viruses · doi:10.3390/v10080412 · Cited by 46
CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases
Hussain, W., Mahmood, T., Hussain, J. S., Ali, N., Shah, T. M., Qayyum, S., & Khan, I. (2018) · Gene · doi:10.1016/j.gene.2018.10.072 · Cited by 46
Novel biologics targeting the P2X7 ion channel
Koch‐Nolte, F., Eichhoff, A. M., Pinto-Espinoza, C., Schwarz, N., Schäfer, T., Menzel, S., Haag, F., Demeules, M., Gondé, H., & Adriouch, S. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.001 · Cited by 51
Lau, C., Ho, J. W., Lo, P. K., & Tin, C. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.04.015 · Cited by 46
New Possibilities on the Horizon: Genome Editing Makes the Whole Genome Accessible for Changes
Kawall, K. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.00525 · Cited by 50
Wang, K., Gong, Q., & Ye, X. (2019) · Theoretical and Applied Genetics · doi:10.1007/s00122-019-03464-4 · Cited by 49
From Genome Sequencing to CRISPR-Based Genome Editing for Climate-Resilient Forest Trees
Cao, H. X., Vu, G. T. H., & Gailing, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020966 · Cited by 56
Moving toward genome-editing therapies for cardiovascular diseases
Musunuru, K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148555 · Cited by 48
Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing
McGaw, C., Garrity, A. J., Munoz, G., Haswell, J. R., Sengupta, S., Keston-Smith, E., Hunnewell, P., Ornstein, A., Bose, M., Wessells, Q. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30465-7 · Cited by 43
Self-citationTariq, A., Mushtaq, M., Yaqoob, H., Bhat, B. A., Zargar, S. M., Raza, A., Ali, S., Charagh, S., Mubarik, M. S., Zaman, Q. U., et al. (2023) · GM Crops & Food · doi:10.1080/21645698.2023.2219111 · Cited by 45
CRISPR based therapeutics: a new paradigm in cancer precision medicine
Das, S., Bano, S., Kapse, P., & Kundu, G. C. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01552-6 · Cited by 47
Li, C., Du, Y., Zhang, T., Wang, H., Hou, Z., Zhang, Y., Cui, W., & Chen, W. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.09.026 · Cited by 48
Recent Therapeutic Gene Editing Applications to Genetic Disorders
Deneault, É. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050255 · Cited by 54
Application of CRISPR/Cas9 to Autophagy Research
O’Prey, J., Sakamaki, J.-I., Baudot, A. D., New, M., Acker, T. V., Tooze, S. A., Long, J. S., & Ryan, K. M. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.09.076 · Cited by 45
Conformational regulation of CRISPR-associated nucleases
Jackson, R. N., van Erp, P. B. G., Sternberg, S. H., & Wiedenheft, B. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.010 · Cited by 48
The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies
Chen, X., Liu, J., Janssen, J. M., & Gonçalves, M. A. F. V. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.005 · Cited by 47
The contribution of alternative splicing to genetic risk for psychiatric disorders
Reble, E., Dineen, A., & Barr, C. L. (2017) · Genes Brain & Behavior · doi:10.1111/gbb.12430 · Cited by 47
Structural insights into the inactivation of CRISPR-Cas systems by diverse anti-CRISPR proteins
Zhu, Y., Zhang, F., & Huang, Z. (2018) · BMC Biology · doi:10.1186/s12915-018-0504-9 · Cited by 47
Self-citationProgrammable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 48
Applied Bioengineering in Tissue Reconstruction, Replacement, and Regeneration
Colazo, J. M., Evans, B. C., Farinas, A. F., Kassis, S. A., Duvall, C. L., & Thayer, W. P. (2019) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2018.0325 · Cited by 49
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 48
Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing
Marina, R. J., Brannan, K. W., Dong, K. D., Yee, B. A., & Yeo, G. W.-M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108350 · Cited by 46
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito
Garrood, W. T., Kranjc, N., Petri, K., Kim, D. Y., Guo, J. A., Hammond, A., Morianou, I., Pattanayak, V., Joung, J. K., Crisanti, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004838117 · Cited by 46
OMICs, Epigenetics, and Genome Editing Techniques for Food and Nutritional Security
Gogolev, Y. V., Ahmar, S., Akpınar, B. A., Budak, H., Kiryushkin, A. S., Gorshkov, V. Y., Hensel, G., Demchenko, K. N., Kovalchuk, I., Mora, F., et al. (2021) · Plants · doi:10.3390/plants10071423 · Cited by 65
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 49
Genome editing and the next generation of antiviral therapy
Stone, D., Niyonzima, N., & Jerome, K. R. (2016) · Human Genetics · doi:10.1007/s00439-016-1686-2 · Cited by 44
Goodman, M., & Malik, P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653729 · Cited by 47
Parsi, K. M., Hennessy, E., Kearns, N. A., & Maehr, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6518-2_16 · Cited by 42
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
